3-Hydroxycapric acid
(Synonyms: 3-羟基癸酸) 目录号 : GC33383A hydroxy fatty acid
Cas No.:14292-26-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
3-hydroxy Decanoic acid is a hydroxy fatty acid and the predominant monomer in methyl-branched poly(3-hydroxyalkanoate) (PHA) polymers produced by P. putida CA-3.1 It is present in LPS from the H. pylori strain SS1 and in the lipid A component of clinical isolates of P. aeruginosa isolated from patients with cystic fibrosis but not the environment or patients with other conditions.2,3 3-hydroxy Decanoic acid inhibits mitotic progression of O. virens pollens via impairment of plasma membrane function.4 It also induces a reversible shape change of the membrane crenation in human erythrocytes. [Matreya, LLC. Catalog No. 1727]
1.O'Connor, S., Szwej, E., Nikodinovic-Runic, J., et al.The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoateBiomaterials34(11)2710-2718(2013) 2.Leker, K., Lozano-Pope, I., Bandyopadhyay, K., et al.Comparison of lipopolysaccharides composition of two different strains of Helicobacter pyloriBMC Microbiol.17(1)226(2017) 3.Ernst, R.K., Moskowitz, S.M., Emerson, J.C., et al.Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosisJ. Infect. Dis.196(7)1088-1092(2007) 4.Kanaho, Y., Sato, T., Fuji, T., et al.Shape-transforming action of myrmicacin (3-hydroxydecanoic acid) and some related compounds on the membrane of intact human erythrocytesChem. Pharm. Bull. (Tokyo)29(10)3063-3066(1981)
Cas No. | 14292-26-3 | SDF | |
别名 | 3-羟基癸酸 | ||
Canonical SMILES | CCCCCCCC(O)CC(O)=O | ||
分子式 | C10H20O3 | 分子量 | 188.26 |
溶解度 | Chloroform: Soluble,Ethanol: Soluble,Methanol: Soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 5.3118 mL | 26.559 mL | 53.118 mL |
5 mM | 1.0624 mL | 5.3118 mL | 10.6236 mL |
10 mM | 0.5312 mL | 2.6559 mL | 5.3118 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。